Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YIV 906

Next Previous
Drug Profile

YIV 906

Alternative Names: KD-018; PHY-906; YIV-906

Latest Information Update: 23 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PhytoCeutica
  • Developer Kadmon Corporation; PhytoCeutica; Yale University; Yiviva
  • Class Chemoprotectants
  • Mechanism of Action Acetylcholinesterase modulators; Cyclo-oxygenase 2 inhibitors; Cytochrome P-450 enzyme system inhibitors; Metalloprotease inhibitors; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; Opioid delta receptor antagonists; P-glycoprotein inhibitors; Tachykinin receptor antagonists; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Liver cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer; Liver cancer
  • Phase I/II Pancreatic cancer
  • Clinical Phase Unknown Rectal cancer
  • Preclinical Inflammatory bowel diseases; Irritable bowel syndrome; Malignant melanoma; Non-small cell lung cancer
  • Discontinued Gastrointestinal disorders

Most Recent Events

  • 30 May 2025 Efficacy and adverse events data from a phase II CALM trial in Liver cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 19 Nov 2024 Yiviva completes phase II CALM trial for Liver cancer in USA, China, Hong Kong, and Taiwan (NCT04000737)
  • 05 Feb 2024 Yiviva completes enrolment in its phase II CALM trial for Liver cancer in USA, China, Hong Kong, and Taiwan (NCT04000737)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top